EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fortrea Holdings's Enterprise Value is €3,577 Mil.
Fortrea Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €102 Mil. Therefore, Fortrea Holdings's EV-to-FCF for today is 35.09.
The historical rank and industry rank for Fortrea Holdings's EV-to-FCF or its related term are showing as below:
FRA:K67'
s EV-to-FCF Range Over the Past 10 Years
Min: 19.19 Med: 33.73 Max: 49.05
Current: 36.95
During the past 4 years, the highest EV-to-FCF of Fortrea Holdings was 49.05. The lowest was 19.19. And the median was 33.73.
FRA:K67's EV-to-FCF is ranked worse than 75.34% of 369
companies
in the Biotechnology industry
Industry Median: 8.9
vs FRA:K67: 36.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Fortrea Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fortrea Holdings's EV-to-FCF
For the Biotechnology subindustry, Fortrea Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's EV-to-FCF falls into.
Fortrea Holdings's current Enterprise Value is €3,577 Mil.
Fortrea Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €102 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (FRA:K67) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Fortrea Holdings's PE Ratio for today is calculated as:
Fortrea Holdings's share price for today is €23.00.
Fortrea Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fortrea Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Fortrea Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:K67 has been successfully added to your 